NEW YORK, April 15, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Cellular Biomedicine Group Inc. shareholders (NASDAQ: CBMG). Concerned CBMG investors who purchased shares are encouraged to contact securities attorney Hamilton Lindley by clicking here.
The law firm's investigation will focus on potential violations of the federal securities laws by Cellular Biomedicine Group Inc. A report was published in SeekingAlpha.com on April 7, 2015 stating that (1) Cellular Biomedicine has achieved an unsustainable $500m valuation by using paid stock promoters; (2) its "Car-T" technology has experienced patient deaths and is worthless; (3) its founders have been the target of multiple allegations of dishonesty; and (4) there are numerous accounting and financial irregularities in its corporate structure and SEC filings. Shares of CBMG have fallen, on this news, as much as $6.30 per share, or more than 24%, to as low as $25.92 in intraday trading on April 7, 2015.
Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. CBMG stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/CBMG.
SOURCE Dunnam & Dunnam